Ocean Biomedical (OCEA) shares were up 88% premarket Wednesday after the company said that its co-founder, Jonathan Kurtis, and his research team have received additional funding from the National Institutes of Health to further their malaria vaccine research.
The company said that recent US Food and Drug Administration guidance on lipid-encapsulated vaccines could provide an expedited development pathway for their approach.
Ocean Biomedical said it could potentially begin human trials as early as Q4.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。